iShares MSCI Malaysia ETF vs Halozyme Therapeutics Inc. Common Stock — how do they compare? iShares MSCI Malaysia ETF trades at $26.66 (market cap $256.41M), while Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 49.1× iShares MSCI Malaysia ETF's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, iShares MSCI Malaysia ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Malaysia ETF for 66 Days and Halozyme Therapeutics Inc. Common Stock for 1 Days on average.
| EWM | HALO | |
|---|---|---|
Market Cap | $256.41M | $12.58B |
Volume | 111,962 | 2,179,278 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.42 | $115.22 |
52-Week Low | $25.33 | $61.63 |
Typical Hold Time | 66 Days | 1 Days |
Enterprise Value | — | $14.49B |
Signals from Pluang's Aura AI — not financial advice
EWM stock trades at $26.66 with minimal daily movement (+0.19%). Technical indicators show conflicting signals with moving averages suggesting bearish pressure while oscillators indicate potential oversold conditions. The stock faces immediate resistance at $27 and support at $26. Recent news highlights regional environmental challenges affecting operations.
The stock presents a cautious outlook with mixed technical signals and limited fundamental data available. Near-term direction will depend on earnings results and management guidance. Key risks include operational disruptions from regional environmental issues and broader market volatility affecting small-cap stocks.
No Aura AI signal available yet.
Trailing returns across standard periods
EWM tracks the MSCI Malaysia Index, providing exposure to the Malaysian equity market. It offers a diversified portfolio of large and mid-sized companies across various sectors in Malaysia.
Read more on EWM →Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →